Literature DB >> 28974989

Rituximab biosimilar in rheumatoid arthritis: an enhanced-evidence assessment to evaluate equivalence with the originator based on network meta-analysis.

Marco Chiumente1, Andrea Messori2.   

Abstract

Entities:  

Year:  2017        PMID： 28974989      PMCID： PMC5613856          DOI： 10.1177/1759720X17721151

Source DB:  PubMed          Journal:  Ther Adv Musculoskelet Dis        ISSN： 1759-720X            Impact factor:   5.346


× No keyword cloud information.
  8 in total

1.  "Total evidence" network meta-analysis as a tool for improving the assessment of biosimilars: application to etanercept in rheumatoid arthritis
.

Authors:  Andrea Messori; Sabrina Trippoli; Claudio Marinai
Journal:  Int J Clin Pharmacol Ther       Date:  2017-06       Impact factor: 1.366

2.  Rheumatologists' Perceptions of Biosimilar Medicines Prescription: Findings from a French Web-Based Survey.

Authors:  Morgane Beck; Bruno Michel; Marie-Christine Rybarczyk-Vigouret; Dominique Levêque; Christelle Sordet; Jean Sibilia; Michel Velten
Journal:  BioDrugs       Date:  2016-12       Impact factor: 5.807

3.  The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.

Authors:  Paul Emery; Roy Fleischmann; Anna Filipowicz-Sosnowska; Joy Schechtman; Leszek Szczepanski; Arthur Kavanaugh; Artur J Racewicz; Ronald F van Vollenhoven; Nicole F Li; Sunil Agarwal; Eva W Hessey; Timothy M Shaw
Journal:  Arthritis Rheum       Date:  2006-05

4.  Network meta-analysis as a tool for improving the effectiveness assessment of biosimilars based on both direct and indirect evidence: application to infliximab in rheumatoid arthritis.

Authors:  Andrea Messori; Sabrina Trippoli; Claudio Marinai
Journal:  Eur J Clin Pharmacol       Date:  2016-12-14       Impact factor: 2.953

5.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Authors:  Jonathan C W Edwards; Leszek Szczepanski; Jacek Szechinski; Anna Filipowicz-Sosnowska; Paul Emery; David R Close; Randall M Stevens; Tim Shaw
Journal:  N Engl J Med       Date:  2004-06-17       Impact factor: 91.245

6.  Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)).

Authors:  P Emery; A Deodhar; W F Rigby; J D Isaacs; B Combe; A J Racewicz; K Latinis; C Abud-Mendoza; L J Szczepanski; R A Roschmann; A Chen; G K Armstrong; W Douglass; H Tyrrell
Journal:  Ann Rheum Dis       Date:  2010-05-20       Impact factor: 19.103

Review 7.  Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis.

Authors:  Glen S Hazlewood; Cheryl Barnabe; George Tomlinson; Deborah Marshall; Dan Devoe; Claire Bombardier
Journal:  BMJ       Date:  2016-04-21

8.  A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis.

Authors:  Dae Hyun Yoo; Chang-Hee Suh; Seung Cheol Shim; Slawomir Jeka; Francisco Fidencio Cons-Molina; Pawel Hrycaj; Piotr Wiland; Eun Young Lee; Francisco G Medina-Rodriguez; Pavel Shesternya; Sebastiao Radominski; Marina Stanislav; Volodymyr Kovalenko; Dong Hyuk Sheen; Leysan Myasoutova; Mie Jin Lim; Jung-Yoon Choe; Sang Joon Lee; Sung Young Lee; Taek Sang Kwon; Won Park
Journal:  Ann Rheum Dis       Date:  2016-09-13       Impact factor: 19.103
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.